



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/016,177	10/25/2001	Avi J. Ashkenazi	GNE.2630P1C90	4438

35489 7590 07/02/2004

HELLER EHRMAN WHITE & MCAULIFFE LLP  
275 MIDDLEFIELD ROAD  
MENLO PARK, CO 94025-3506

EXAMINER
----------

SAUD, CHRISTINE J

ART UNIT	PAPER NUMBER
----------	--------------

1647

DATE MAILED: 07/02/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	10/016,177		ASHKENAZI ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	Christine J. Saoud		1647	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 58-77 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 58-77 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |  |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>030404 4/30/02</u> | 6) <input type="checkbox"/> Other: ____  |

## **DETAILED ACTION**

### ***Status of the Claims***

Claims 58-77 are pending in the instant application. Claims 1-57 have been canceled and claims 58-77 added as requested by Applicant in the amendment filed 25 October 2001.

### ***Priority***

Applicant has amended the priority claim in the first line of the specification in the Paper filed 03 September 2002.

### ***Specification***

The disclosure is objected to because it contains embedded hyperlinks and/or other forms of browser-executable code. See at least page 124, line 37 and page 127, line 18. The specification should be carefully reviewed for any other occurrences of hyperlinks. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

### ***Formal Matters***

The deposit of biological organisms is considered by the Examiner to be necessary for enablement of the current invention (see MPEP Chapter 2400 and 37 C.F.R. § 1.801-1.809. Examiner acknowledges the deposit of organisms under accession number ATCC 209905 under terms of the Budapest Treaty on

Art Unit: 1647

International Recognition of the Deposit of Microorganisms for the Purposes of  
Patent procedure in compliance with this requirement.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 58-63 and 70-77 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The invention appears to employ novel biological materials, specifically the cDNA deposited under ATCC accession number 209905. Since the biological materials are essential to the claimed invention they must be obtainable by a repeatable method set forth in the specification or otherwise readily available to the public. If the biological materials are not so obtainable or available, the requirements of 35 U.S.C. § 112 may be satisfied by a deposit of the biological materials. The specification does not disclose a repeatable process to obtain the biological materials and it is not apparent if the biological materials are readily available to the public. It is noted that Applicant has deposited the biological materials, but there is no indication in the specification as to public availability. If the deposit is made under the Budapest Treaty, then an affidavit or declaration by Applicant, or a statement by an attorney of record over his or her signature and registration number, stating

Art Unit: 1647

that the specific biological materials have been deposited under the Budapest Treaty and that the biological materials will be irrevocably and without restriction or condition released to the public upon the issuance of a patent, would satisfy the deposit requirement made herein. If the deposit has not been made under the Budapest Treaty, then in order to certify that the deposit meets the criteria set forth in 37 C.F.R. §§ 1.801-1.809, Applicant may provide assurance of compliance by an affidavit or declaration, or by a statement by an attorney of record over his or her signature and registration number, showing that:

(a) during the pendency of this application, access to the invention will be afforded to the Commissioner upon request;

(b) all restrictions upon availability to the public will be irrevocably removed upon granting of the patent;

(c) the deposit will be maintained in a public depository for a period of 30 years or 5 years after the last request or for the effective life of the patent, whichever is longer;

(d) a test of the viability of the biological material at the time of deposit will be made (see 37 C.F.R. § 1.807); and

(e) the deposit will be replaced if it should ever become inviable.

Applicant's attention is directed to M.P.E.P. §2400 in general, and specifically to §2411.05, as well as to 37 C.F.R. § 1.809(d), wherein it is set forth that "the specification shall contain the accession number for the deposit, the date of the deposit, the name and address of the depository, and a description of the deposited material sufficient to specifically identify it and to permit

Art Unit: 1647

examination.” The specification should be amended to include this information, however, Applicant is cautioned to avoid the entry of new matter into the specification by adding any other information

Claims 58-62 and 71-77 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to isolated nucleic acids encoding polypeptides having at least 80%, 85%, 90%, 95% or 99% sequence identity with a particular disclosed sequence, and variants and fragments thereof (as encompassed by the hybridization language). The claims do not require that the polypeptide possess any particular biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. Thus, the claims are drawn to a genus of nucleic acids that is defined only by sequence identity or hybridization ability.

To provide evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity or hybridization ability. There is not even

Art Unit: 1647

identification of any particular portion of the structure that must be conserved.

Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

*Vas-Cath Inc. v. Mahurkar*, 19USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Art Unit: 1647

Therefore, only isolated polynucleotides encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:352, but not the full breadth of the claims meets the written description provision of 35 U.S.C. § 112, first paragraph. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

Claims 58-62 and 74-77 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is undue include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. In re Wands, 858, F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

The claims are drawn to nucleic acids encoding a polypeptide having at least 80%-99% amino acid sequence identity to the polypeptide of SEQ ID NO:352 or the extracellular domain thereof, both referred to as PRO1114. There



is no functional limitation in the claims. The claims encompass an unreasonable number of inoperative polypeptides, which the skilled artisan would not know how to use. While the specification suggests that the polypeptide of SEQ ID NO:352 has some amino acid sequence identity to interferon receptors (see page 277 of the specification), the claims require no function for the polypeptides being claimed. As opposed to the claims, what is disclosed about PRO1114 is narrow: a single polypeptide with a particular function. The skill in the art does not make up for the deficiencies in the specification as to the function of the claimed protein. There are no working examples of polypeptides less than 100% identical to the polypeptide of SEQ ID NO:352 or the mature form thereof. The specification does not provide guidance for using polypeptide related to (i.e., 80%-99% identity) SEQ ID NO:352 without the function of the polypeptide of SEQ ID NO:352. The claims are broad because they do not require the claimed polypeptide to be identical to the disclosed sequence and because the claims have no functional limitation.

For these reasons, which include the complexity and unpredictability of the nature of the invention and the lack of knowledge about the function(s) of encompassed polypeptides structurally related to PRO1114 having the amino acid sequence of SEQ ID NO:352, the one example of PRO1114, the lack of direction or guidance for using the polypeptide of SEQ ID NO:352 or polypeptides which are structurally related by amino acid sequence, and the breadth of the claims for structure without function, it would require undue experimentation to use the invention commensurate in scope with the claims.

***35 U.S.C. § 112, Second Paragraph***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

Art Unit: 1647

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 58-77 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The protein identified as PRO1114 may be a soluble protein or it may be a receptor protein. Accordingly, the limitation that the claimed nucleic acid encodes a protein which comprises an "extracellular domain" (for example, see claim 58, parts (c) and (d)) is indefinite, as the art does not recognize soluble proteins as having such domains. Further, if the protein had an extracellular domain, the recitation of "the extracellular domain" ... "lacking its associated signal sequence" (claim 58, part (d), for example) is indefinite as a signal sequence is not generally considered to be part of an extracellular domain, as signal sequences are cleaved from said domains in the process of secretion from the cell. Clarification is required.

Claim 72 recites "wherein said hybridization occurs under stringent conditions". This recitation is vague and indefinite because depending on the various conditions which may be considered "stringent", a number of different molecules could be obtained following a hybridization procedure. Without knowing the metes and bounds of "stringent conditions", the skilled artisan would not know what is encompassed by the instant claims.

***Priority Determination***

The claimed subject matter is found to have utility based on a positive result in the fetal hemoglobin induction assay (Example 127, assay 107; see page 351 of the specification). This activity was at least disclosed in PCT/US00/04341 which was filed 18 February 2000.

Provisional application nos. 60/087,106 and 60/094,651 fail to disclose any activity for the claimed protein. '106 and '651 assert that the disclosed protein share amino acid sequence similarity to the cytokine receptor family of proteins, however, without more, one of ordinary skill in the art would not be able to use the claimed protein. This is because assignment to the "cytokine receptor family" does not provide a specific, substantial and credible utility for the claimed protein because each of the receptors of the cytokine receptor family have different biological roles based on their expression patterns and the ligands which they bind. Therefore, the knowledge that the claimed protein may be a cytokine receptor does not provide a specific and substantial utility for the claimed protein, and therefore, the claimed invention does not obtain priority benefit to these applications due to lack of utility and enablement under 35 U.S.C. §§ 101 and 112, first paragraph, respectively.

It is not clear if the activity in the fetal hemoglobin induction assay was disclosed in U.S. Application No. 09/380,138 as this application is unavailable at the time of the instant Office action. Therefore, the effective priority date for this application is assumed to be 18 February 2000, which is the date for which utility

Art Unit: 1647

and enablement can be confirmed. Applicant is invited to provide evidence and support for utility and enablement in the earlier applications, and the application of art will be reconsidered at that time.

***Claim Rejections - 35 USC § 102***

- The following is a quotation of the appropriate paragraphs of 35

U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 58-67 and 70-77 are rejected under 35 U.S.C. 102(e) as being anticipated by Parham et al. (U.S. Pat. No. 6,586,228).

Parham et al. disclose a nucleic acid molecule (SEQ ID NO:1) encoding a protein (SEQ ID NO :2) which has an amino acid sequence at least 98% identical to that of the claimed protein of SEQ ID NO:352. The nucleic acid molecule of

Art Unit: 1647

Parham et al. is 98.1% identical over a stretch of over 1300 bases. Parham et al. additionally disclose that amino acids at positions 146, 148, 171, and 214 could be variable and are listed as Xaa. According to Table 1, the amino acids provided for the claimed protein of SEQ ID NO:352 are encompassed and contemplated by Parham et al., therefore, the reference anticipates the instant claims. Parham et al. additionally disclose vectors and host cells. Therefore, the claims are anticipated by the teachings of Parham et al., absent evidence to the contrary

### ***Conclusion***

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine J. Saoud whose telephone number is 571-272-0891. The examiner can normally be reached on mttr, 8:00-2:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on 571-272-0887. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1647

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**CHRISTINE J. SAUD  
PRIMARY EXAMINER**

*Christine J. Saud*